NCCN Guidelines Now Recommend Boehringer Ingelheim’s Hernexeos for HER2-Mutant NSCLC

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) to recommend Boehringer Ingelheim’s Hernexeos (zongertinib tablets) as an initial treatment option for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). This recommendation, reflected in Version 5.2026 of the NCCN Guidelines updated on March 13, 2026, marks a significant step forward in targeted therapy for this patient population.

HER2-Mutant NSCLC and the Role of Targeted Therapy

HER2-mutant NSCLC is a specific subtype of lung cancer characterized by alterations in the HER2 gene. Targeted therapies, like Hernexeos, are designed to specifically attack cancer cells with these mutations, offering a more precise approach compared to traditional chemotherapy. The NCCN recommendation highlights the growing recognition of the importance of targeted therapies in treating this disease.

Hernexeos: A Preferred Treatment Option

Hernexeos received a preferred recommendation as a subsequent therapy in August 2025, according to Boehringer Ingelheim. The latest NCCN update now positions Hernexeos as an initial treatment option. This means clinicians can consider Hernexeos earlier in the treatment pathway for eligible patients. Onclive and OncNursing News also reported on the NCCN’s addition of zongertinib to its guidelines.

Implications for Patients

The NCCN Guidelines are widely used by healthcare professionals to develop informed decisions about cancer treatment. This updated recommendation provides clinicians with evidence-based support for using Hernexeos in appropriate patients with HER2-mutant advanced NSCLC. Patients diagnosed with this subtype of lung cancer should discuss treatment options, including Hernexeos, with their oncologist to determine the most suitable course of action.